Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2000): Poole PJ+, Cochrane Database Syst Rev (4), CD002733
Angioedema
Bullous dermatitis
(2003): Augey F+, Ann Dermatol Venereol 130(11), 1058
Bullous pemphigoid
(2006): Garcia-Doval I+, Br J Dermatol 155(4), 820 (%)
Fixed eruption
(2001): Garcia-Doval I+, Acta Derm Venereol 81(6), 450
Gianotti–Crosti syndrome
(2002): Haug S+, Hautarzt 53(10), 683 (4 cases)
Henoch-Schonlein purpura
(2001): Watanabe T+, Pediatr Nephrol 16(5), 458
Impetigo
(2004): France EK+, Arch Pediatr Adolesc Med 158(11), 1031 (9
cases)
Linear IgA dermatosis
(2000): Boyce TG+, Vaccine 19(2-3), 217 (26–35%)
Pemphigus
(2000): Mignogna MD+, Int J Dermatol 39(10), 800
Purpura
(2006): Tishler M+, Isr Med Assoc J 8(5), 322
(2002): Yanai-Berar N+, Clin Nephrol 58(3), 220 (1 case)
Rash (sic)
(2004): Prescrire Int 13(74), 206 (with squalene adjuvant)
(2004): Hesley TM+, Pediatr Infect Dis J 23(3), 240 (with
hepatitis B, measles-mumps-rubella, and varicella vaccine)
(2000): Lohiya GS, Am J Infect Control 28(5), 386
Shivering
(2004): Kanra G+, Pediatr Infect Dis J 23(4), 300 (%)
Side effects (sic)
(2004): de Bruijn IA+, Virus Res 103(1-2), 139 (transient)
(2003): Allsup S+, Health Technol Assess 7(24), iii
(2003): Bodkin C+, Int J Nurs Pract 9(6), 382
(2002): Williams JP+, Am J Manag Care 8(5 Suppl), S143 (mild)
Toxicoderma
(2000): Manzano E+, Aten Primaria 26(6), 429
Vasculitis
(2006): Famularo G+, J Clin Rheumatol 12(1), 48
(2004): Hull JH+, J Neurol Neurosurg Psychiatry 75(10), 1507
(2004): Walker SL+, Clin Exp Dermatol 29(1), 95
(2003): Iyngkaran P+, Rheumatology (Oxford) 42(7), 907
(2003): Ritter O+, Z Kardiol 92(11), 962
(2003): Tavadia S+, Clin Exp Dermatol 28(2), 154 (4 cases)
(2002): Yanai-Berar N+, Clin Nephrol 58(3), 220 (1 case)
Eyes
Oculorespiratory syndrome*
(2005): Can Commun Dis Rep 31(21), 217
(2004): De Serres G+, Arch Intern Med 164(20), 2266 (15–34%)
(2004): Grenier JL+, CanCommunDisRep30(2), 9
(2003): De Serres G+, Vaccine 21(19-20), 2346 (4–5%)
(2003): Fredette MJ+, Clin Infect Dis 37(8), 1136 (6 cases)
(2003): Scheifele DW+, Clin Infect Dis 36(7), 850 (3%)
(2003): Skowronski DM+, Clin Infect Dis 36(6), 705 (13–27%)
(2003): Skowronski DM+, Clin Infect Dis 37(8), 1059
(2003): Skowronski DM+, JInfectDis187(3), 495
(2002): Orr P, CanCommunDisRep28, 1
(2002): Skowronski DM+, CMAJ 167(8), 853 (5%)
(2002): Skowronski DM+, Vaccine 20(21-22), 2713
(2001): Boulianne N+, Can Commun Dis Rep 27(10), 85
(2000): Can Commun Dis Rep 26(23), 201
(2000): Vilain S+, Bull Soc Belge Ophtalmol (277), 71
Other
Abdominal pain
(2002): Piedra PA, Semin Pediatr Infect Dis 13(2), 90 (2%)
(2002): Piedra PA+, Pediatrics 110(4), 662
Anaphylactoid reactions/Anaphylaxis (rare)
(2005): Izurieta HS+, JAMA 294(21), 2720
INFLUENZA VACCINES 295
Chills
(2003): Frey S+, Vaccine 21(27-30), 4234 (mild)
Cough
(2000): Schaad UB+, Antimicrob Agents Chemother 44(5), 1163
Fever
(2006): Skowronski DM+, Pediatrics 117(6), 1963
(2004): D’Alessandro D+, Indian J Med Res 119 Suppl, 108
(2004): Hesley TM+, Pediatr Infect Dis J 23(3), 240 (with
hepatitis B, measles-mumps-rubella, and varicella vaccine)
(2004): Kanra G+, Pediatr Infect Dis J 23(4), 300 (6–8%)
(2004): Socan M+, Vaccine 22(23-24), 3087
(2003): Dong PM+, Zhonghua Liu Xing Bing Xue Za Zhi
24(7), 570 (2–6%)
(2003): Squarcione S+, Vaccine 21(11-12), 1268 (%)
(2002): Galaj A+, Pol Merkuriusz Lek 12(72), 496 (1%)
(2002): Piedra PA+, Pediatrics 110(4), 662
(2001): Zangwill KM+, Pediatr Infect Dis J 20(8), 740
Hypersensitivity
(2003): Skowronski DM+, JInfectDis187(3), 495
Injection-site edema
(2004): Socan M+, Vaccine 22(23-24), 3087
(2002): Galaj A+, Pol Merkuriusz Lek 12(72), 496 (7%)
(2002): Kawahara H+, Arerugi 51(7), 559 (1 case)
(2001): Schmitt-Grohe S+, Klin Padiatr 213(6), 338
Injection-site erythema
(2004): Kanra G+, Pediatr Infect Dis J 23(4), 300 (9–11%)
(2004): Socan M+, Vaccine 22(23-24), 3087
(2002): Gaeta GB+, Vaccine 20 Suppl 5, B33
(2002): Galaj A+, Pol Merkuriusz Lek 12(72), 496 (1%)
(2001): Schmitt-Grohe S+, Klin Padiatr 213(6), 338
(2000): Banzhoff A+, Immunol Lett 71(2), 91 (53%)
(2000): Murayama N+, Kansenshogaku Zasshi 74(1), 30
Injection-site induration
(2004): Prescrire Int 13(74), 206 (with squalene adjuvant)
(2004): D’Alessandro D+, Indian J Med Res 119 Suppl, 108
(2004): Kanra G+, Pediatr Infect Dis J 23(4), 300 (9%)
(2001): Schmitt-Grohe+, Klin Padiatr 213(6), 338
(2000): Banzhoff A+, Immunol Lett 71(2), 91 (53%)
Injection-site inflammation
(2004): Belshe RB+, NEnglJMed351(22), 2286
(2003): Frey S+, Vaccine 21(27-30), 4234 (mild)
(2003): Squarcione S+, Vaccine 21(11-12), 1268
Injection-site pain (20–28%)
(2004): Prescrire Int 13(74), 206 (with squalene adjuvant)
(2004): Belshe RB+, NEnglJMed351(22), 2286
(2004): Cooper CL+, Vaccine 22(23-24), 3136
(2004): Kanra G+, Pediatr Infect Dis J 23(4), 300 (24–25%)
(2003): Ben-Yehuda A+, JMedVirol69(4), 560
(2003): Donalisio MR+, Rev Soc Bras Med Trop 36(4), 467 (12%)
(2003): Frey S+, Vaccine 21(27-30), 4234 (mild)
(2002): Galaj A+, Pol Merkuriusz Lek 12(72), 496 (1%)
(2001): Gasparini R+, Eur J Epidemiol 17(2), 135 (mild)
(2001): Jackson LA+, Vaccine 19(32), 4703
(2001): Schmitt-Grohe S+, Klin Padiatr 213(6), 338
(2000): Banzhoff A+, Immunol Lett 2000 Feb 1;71(2), 91 (53%)
(2000): Schaad UB+, Antimicrob Agents Chemother 44(5), 1163
(42–57%)
Injection-site papules & nodules
(2000): Gonzalez M+, Arch Dis Child 2000 Dec; 83(6), 488
(mild)
Injection-site reactions (sic)
(2002): Redding G+, Pediatr Infect Dis J 21(1), 44
(2001): Allsup SJ+, Gerontology 47(6), 311 (11%)
Myalgia/Myositis/Myopathy/Myotoxicity
(2004): Prescrire Int 13(74), 206 (with squalene adjuvant)
(2004): D’Alessandro D+, Indian J Med Res 119 Suppl, 108
(2004): Iyoda K+, No To Hattatsu 36(5), 401
(2004): Socan M+, Vaccine 22(23-24), 3087
(2003): Frey S+, Vaccine 21(27-30), 4234 (mild)